利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

20 条记录 (耗时 0.014 秒)

    METHODS OF MAKING AND USING N-DESMETHYLZOPICLONE
    2.
    发明公开
    METHODS OF MAKING AND USING N-DESMETHYLZOPICLONE 审中-公开
    制备和使用N-去甲基明戈酮的方法

    公开(公告)号：EP1183030A1

    公开(公告)日：2002-03-06

    申请号：EP00930565.7

    申请日：2000-05-11

    申请人： Sepracor Inc.

    发明人： JERUSSI, Thomas, P. ,  SENANAYAKE, Chrisantha, H. ,  RUBIN, Paul, D. ,  HONG, Yaping ,  BAKALE, Roger, A. ,  XIANG, Tingjian ,  MCCONVILLE, Fran, A.

    IPC分类号： A61K31/495

    CPC分类号： A61K31/4985 ,  A61K31/498 ,  C07B2200/07 ,  C07D487/04

    摘要： The invention is directed to compositions comprising, and methods of using, racemic N-desmethylzopiclone, optically pure (+)-N-desmethylzopiclone, and optically pure (-)-N-desmethylzopiclone in the treatment and prevention of diseases and conditions in mammals. The invention is further directed to novel methods of preparing N-desmethylzopiclone, optically pure (+)-N-desmethylzopiclone, and optically pure (-)-N-desmethylzopiclone.

    摘要翻译： 本发明涉及包含外消旋N-去甲基佐匹克隆，光学纯（+） - N-去甲基佐匹克隆和光学纯（ - ）-N-去甲基佐匹克隆用于治疗和预防哺乳动物疾病和病症的组合物和方法。 本发明还涉及制备N-去甲基佐匹克隆，光学纯（+）-N-去甲基佐匹克隆和光学纯（ - ）-N-去甲基佐匹克隆的新方法。

    METHODS OF USING AND COMPOSITIONS COMPRISING DOPAMINE REUPTAKE INHIBITORS
    3.
    发明授权
    METHODS OF USING AND COMPOSITIONS COMPRISING DOPAMINE REUPTAKE INHIBITORS 有权
    使用方法及套DOPAMINEWIEDERAUFNAHMEINHIBITOR CONTAIN

    公开(公告)号：EP1107746B1

    公开(公告)日：2004-10-13

    申请号：EP99945137.0

    申请日：1999-08-23

    申请人： Sepracor Inc.

    发明人： JERUSSI, Thomas, P. ,  SENANAYAKE, Chrisantha, H. ,  FANG, Qun, K.

    IPC分类号： A61K31/13 ,  A61K31/135 ,  A61P25/28

    CPC分类号： A61K45/06 ,  A61K31/11 ,  A61K31/135 ,  A61K31/137 ,  A61K2300/00

    摘要： Methods are disclosed for the treatment and prevention of disorders and conditions including, but are not limited to, erectile dysfunction, affective disorders, weight gain, cerebral functional disorders, pain, obsessive-compulsive disorder, substance abuse, chronic disorders, anxiety, eating disorders, migraines, incontinence, depresson, attention deficit disorder, attention deficit disorder with hyperactivity, bipolar and manic conditions, dysthymic disorder, and cyclothymic disorder, senile dementia, Alzheimer's type dementia, memory loss, amnesia/amnestic syndrome, disturbance of consciousness, coma, lowering of attention, speech disorders, Parkinson's disease, Lennox syndrome, autism, epilepsy, hyperkinetic syndrome and schizophrenia. The methods comprise the administration of a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Pharmaceutical compositions and dosage forms are also disclosed that comprise a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Preferred dopamine reuptake inhibitors are racemic or optionally pure sibutramine metabolites, wherein the sibutramine metabolite is selected from the group consisting of (+)-desmethylsibutramine, (-)-desmethylsibutramine, (±)-desmethylsibutramine, (+)-didesmethylsibutramine, (-)-didesmethylsibutramine, and (±)-didesmethylsibutramine.

    METHODS AND COMPOSITIONS FOR TREATING GASTRO-ESOPHAGEAL REFLUX DISEASE
    4.
    发明公开
    METHODS AND COMPOSITIONS FOR TREATING GASTRO-ESOPHAGEAL REFLUX DISEASE 审中-公开
    方法和组合物胃食管反流治疗

    公开(公告)号：EP1100502A1

    公开(公告)日：2001-05-23

    申请号：EP99935877.3

    申请日：1999-07-23

    申请人： Sepracor Inc.

    发明人： MCCULLOUGH, John, R. ,  JERUSSI, Thomas, P.

    IPC分类号： A61K31/445

    CPC分类号： A61K31/495 ,  A61K31/4468 ,  A61K2300/00

    摘要： Compositions employing and methods utilizing the optically pure (+) isomer of norcisapride are disclosed. This compound has surprisingly been found to be a potent drug for the treatment of disorders of the central nervous system. The compound, (+) norcisapride, has also been found to be a potent antiemetic agent. Finally, the (+) isomer of norcisapride also avoids certain adverse side effects and certain adverse drug interactions. The compound is further useful for treating gastro-intestinal motility dysfunction, gastro-esophageal reflux disease, dyspepsia, gastroparesis, intestinal pseudo-obstruction. It has a prokinetic effect.

    METHODS OF USING AND COMPOSITIONS COMPRISING DOPAMINE REUPTAKE INHIBITORS
    8.
    发明公开
    METHODS OF USING AND COMPOSITIONS COMPRISING DOPAMINE REUPTAKE INHIBITORS 有权
    包含多巴胺再摄取抑制剂的使用方法和组合物

    公开(公告)号：EP1107746A2

    公开(公告)日：2001-06-20

    申请号：EP99945137.0

    申请日：1999-08-23

    申请人： Sepracor Inc.

    发明人： JERUSSI, Thomas, P. ,  SENANAYAKE, Chrisantha, H. ,  FANG, Qun, K.

    IPC分类号： A61K31/13 ,  A61K31/135

    CPC分类号： A61K45/06 ,  A61K31/11 ,  A61K31/135 ,  A61K31/137 ,  A61K2300/00

    摘要： Methods are disclosed for the treatment and prevention of disorders and conditions including, but are not limited to, erectile dysfunction, affective disorders, weight gain, cerebral functional disorders, pain, obsessive-compulsive disorder, substance abuse, chronic disorders, anxiety, eating disorders, migraines, incontinence, depresson, attention deficit disorder, attention deficit disorder with hyperactivity, bipolar and manic conditions, dysthymic disorder, and cyclothymic disorder, senile dementia, Alzheimer's type dementia, memory loss, amnesia/amnestic syndrome, disturbance of consciousness, coma, lowering of attention, speech disorders, Parkinson's disease, Lennox syndrome, autism, epilepsy, hyperkinetic syndrome and schizophrenia. The methods comprise the administration of a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Pharmaceutical compositions and dosage forms are also disclosed that comprise a dopamine reuptake inhibitor and optionally an additional pharmacologically active compound. Preferred dopamine reuptake inhibitors are racemic or optionally pure sibutramine metabolites, wherein the sibutramine metabolite is selected from the group consisting of (+)-desmethylsibutramine, (-)-desmethylsibutramine, (±)-desmethylsibutramine, (+)-didesmethylsibutramine, (-)-didesmethylsibutramine, and (±)-didesmethylsibutramine.

    摘要翻译： 公开了用于治疗和预防疾病和病症的方法，所述疾病和病症包括但不限于勃起功能障碍，情感障碍，体重增加，大脑功能障碍，疼痛，强迫症，物质滥用，慢性障碍，焦虑，进食障碍 ，偏头痛和失禁。 该方法包括给予多巴胺重摄取抑制剂和任选的另外的药理活性化合物。 还公开了药物组合物和剂型，其包含多巴胺重摄取抑制剂和任选的另外的药理学活性化合物。 优选的多巴胺再摄取抑制剂是外消旋或光学纯的西布曲明代谢物，如去甲基班布丁胺和二去甲基班布丁胺及其药学上可接受的盐，溶剂合物和包合物。 优选的其他药理活性化合物包括影响中枢神经系统的药物，例如5-HT 3拮抗剂。